Key facts
- Notable investors include Proxima Ventures (China), Pudong Capital, Chaosheng Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tuanxiang Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Tuanxiang Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tuanxiang Pharmaceutical
Developer of molecular glue and liquid-liquid phase separation technology designed for undruggable targets and refractory diseases. The company is engaged in new drug research and development, utilizing globally leading and unique phase separation technology, which focuses on undruggable targets and refractory diseases, thereby enabling patients to receive advanced treatment.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Tuanxiang Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tuanxiang Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tuanxiang Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.